SureTrader
Home > Boards > US Listed > Biotechs > Advaxis, Inc. (ADXS)

Blue, there's no doubt in my mind that

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
hdwrsft Member Profile
 
Followed By 5
Posts 1,731
Boards Moderated 0
Alias Born 07/14/16
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 2/15/2018 5:29:09 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2018 5:33:13 PM
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of M... Business Wire - 2/13/2018 8:30:00 AM
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic ... Business Wire - 2/12/2018 9:15:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/6/2018 5:02:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/29/2018 5:04:42 PM
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conferen... Business Wire - 1/29/2018 8:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 1/25/2018 5:04:55 PM
Traders News Source Issues Stocks on Watch and a New Feature Report InvestorsHub NewsWire - 1/25/2018 8:05:00 AM
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in Internation... Business Wire - 1/25/2018 8:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 1/9/2018 5:18:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:02:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:01:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 12/21/2017 6:05:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2017 4:21:23 PM
Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update Business Wire - 12/20/2017 4:15:00 PM
Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic PR Newswire (US) - 12/20/2017 8:05:00 AM
Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017 Business Wire - 12/14/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/4/2017 4:35:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/4/2017 4:31:53 PM
Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma PR Newswire (US) - 11/27/2017 7:05:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 11/9/2017 5:25:39 PM
hdwrsft   Tuesday, 11/15/16 06:52:01 PM
Re: blueyedcatch post# 8268
Post # of 55454 
Blue, there's no doubt in my mind that the deal wheel will be spinning, IMO.

For example, On September 28, 2016, Pfizer (PFE) announced the completion of its acquisition of Medivation for around $14 billion. This deal has added leading metastatic prostate cancer drug Xtandi to Pfizer’s oncology portfolio.

14Bil!!! Holy moly!

Well, guess what, we'll have prostate data next quarter on top of GOG full data presentation AND an ADXS-NEO IND (Will that trigger a milestone payment??)


Next month:
-----------

Preclinical data presentation (ImVACS, December 2016)


Calendar Q1-2017:
-----------------

(Cervical) GOG-0265 full data presentation – (1H 2017)
(Prostate) Preliminary data from ADXS-PSA + pembrolizumab cohorts A + B (1H 2017)
(NEO) ADXS-NEO Active IND (1H 2017)


Calendar Q2-2017:
-----------------
(Cervical plus Head&Neck) AXAL + durvalumab cervical/head & neck – updated data (2H 2017)
(AnalCancer) FAWCETT Stage 1 data (2H 2017)


ASCO 2017 - June 2-6, 2017 Chicago, Illinois:
---------------------------------------

(Anal) Ph 2 BrUOG – 11 patients update (ASCO 2017*)
(Head&Neck) Mt Sinai/Baylor Ph 2 Head & Neck (ASCO 2017*)
(Pediatric Osteosarcoma) COG study in pediatric osteosarcoma study start (1H 2017) • Preliminary Phase 1 data (ASCO 2017*)


Q1/Q2-2018:
-----------

(Prostate) ADXS-PSA + pembrolizumab – complete enrollment of expansion cohort
(Q4 2017); data (1H 2018)


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist